A Prospective Study of Eplerenone in the Treatment of Patients with Glomerulonephritis.

ABSTRACT:

Background

High aldosterone levels contribute to kidney disease progression, while spironolactone in combination with ACEi or ARBs can potentially reduce proteinuria and ameliorate kidney function deterioration. However, evidence on the impact of eplerenone in patients with glomerulonephritis is scarce.

Methods

In this prospective observational study, we assessed the effects of eplerenone in patients with biopsy-proven glomerulonephritis who were already treated with ACEi or ARBs. Patients received either eplerenone (25 mg daily) on top of ACEi or ARBs or standard treatment alone. Proteinuria (24 h total protein excretion), kidney function, blood pressure and serum K⁺ levels were assessed at 3, 6 and 12 months after the initiation of treatment.

Results

Sixt

SUBMITTER: Papasotiriou M 

PROVIDER: S-EPMC10741749 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature